Literature DB >> 32275233

Contributing risk factors towards the prevalence of multidrug-resistant tuberculosis in Malaysia: A systematic review.

Mahindran Rajendran1, Rafdzah Ahmad Zaki1, Nasrin Aghamohammadi2.   

Abstract

Multidrug-resistant tuberculosis (MDR-TB) is one of the causes of morbidity and mortality, among tuberculosis (TB) patients in Malaysia. The purpose of this study was to determine the contributing risk factors to the prevalence of (MDR-TB). Based on systematic review of the literatures, the prevalence of (MDR-TB) and associated risk factors in Malaysia were studied. A comprehensive search of Scopus, Science direct, PubMed, DOAJ, CINAHL Plus, MyJournal, BIREME, BMC Public Health, Medline, CAB, and WoS databases were done among the articles published from 31st January 2009 to 31st December 2018, by using medical subject heading (MeSH) key terms. In conducting this study, a total of 121 papers were reviewed and 23 research papers were chosen, because, they met the specific inclusion criteria. In this study, gender, age, marital status, ethnicity, homeless status, living in urban area and history of imprisonment were evaluated as demographic factors, while educational level and employment were evaluated as socioeconomic factors. Smoking, diabetes mellitus, drug abuse and alcohol consumption were evaluated as behavioral and co-morbidities factors. All the studies chosen as eligible to be included in this study were found to be significantly associated with the risk factors for the prevalence of (MDR-TB). It was also discovered that, lack of adequate knowledge among the community and (TB) patients might increase the progression of (MDR-TB) infection in Malaysia. Thus, carried out a systematic review provided a comprehensive assessment of the (MDR-TB) which might be useful for policy makers, health experts and researchers to implement appropriate strategies for (TB) infected population in Malaysia.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  MDR-TB; Malaysia; Multidrug-resistant; Risk factors; TB; Tuberculosis

Year:  2020        PMID: 32275233     DOI: 10.1016/j.tube.2020.101925

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN: 1472-9792            Impact factor:   3.131


  5 in total

1.  Homelessness and health-related outcomes: an umbrella review of observational studies and randomized controlled trials.

Authors:  Michele Fornaro; Elena Dragioti; Michele De Prisco; Martina Billeci; Anna Maria Mondin; Raffaella Calati; Lee Smith; Simon Hatcher; Mark Kaluzienski; Jess G Fiedorowicz; Marco Solmi; Andrea de Bartolomeis; André F Carvalho
Journal:  BMC Med       Date:  2022-07-12       Impact factor: 11.150

2.  Activation Phenotype of Mycobacterium tuberculosis-Specific CD4+ T Cells Promoting the Discrimination Between Active Tuberculosis and Latent Tuberculosis Infection.

Authors:  Ying Luo; Ying Xue; Liyan Mao; Qun Lin; Guoxing Tang; Huijuan Song; Wei Liu; Shutao Tong; Hongyan Hou; Min Huang; Renren Ouyang; Feng Wang; Ziyong Sun
Journal:  Front Immunol       Date:  2021-08-26       Impact factor: 7.561

3.  Key factors influencing multidrug-resistant tuberculosis in patients under anti-tuberculosis treatment in two centres in Burundi: a mixed effect modelling study.

Authors:  Arnaud Iradukunda; Gabin-Pacifique Ndayishimiye; Darlene Sinarinzi; Emmanuel Nene Odjidja; Nestor Ntakaburimvo; Innocent Nshimirimana; Cheilla Izere
Journal:  BMC Public Health       Date:  2021-11-23       Impact factor: 3.295

4.  Drug Resistance Patterns and Trends in Patients with Suspected Drug-Resistant Tuberculosis in Dalian, China: A Retrospective Study.

Authors:  Yuanping Pan; Yingying Yu; Jiachen Lu; Yaohui Yi; Xiaofeng Dou; Ling Zhou
Journal:  Infect Drug Resist       Date:  2022-07-30       Impact factor: 4.177

5.  Prevalence of multidrug-resistant tuberculosis in East Africa: A systematic review and meta-analysis.

Authors:  Kindu Alem Molla; Melese Abate Reta; Yonas Yimam Ayene
Journal:  PLoS One       Date:  2022-06-30       Impact factor: 3.752

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.